Oric Pharmaceuticals, Inc.

Venture-backed company · Stage unknown· South San Francisco, CAoricpharma.com
Rounds on record
2
Latest round
May 29, 2025
Form D equity offering
Latest round size
$125M
Form D industry: Biotechnology

Public company. Publicly listed (ORIC); its private filings are not venture rounds.

More
Ask DFX about thisView relationshipsFinancing historyInvestorsOwnership and outcomes
As of · the latest observation of this company; each round carries its own date

3 additional officers and directors

Every relationship, signal and contact on this record, with the source on each.

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

What matters now

  1. 2 investors
    named

    2 investors on record.

    The investors already on the cap table shape who leads the next round.

    Factfunding announcements, portfolio pages and Form DFor Investors, foundersInvestors →
  2. 6 directors
    board

    6 directors on record from Form D filings and board-seat attributions.

    The board is who decides on the next round and on a sale.

    FactSEC Form D related personsFor Investors, acquirersPeople →
Drawing the relationship network…
Facts
Year of incorporation
unknown
Revenue range (Form D)
Decline to Disclosesec.gov
Rounds on record
2
Disclosed raised
unknownsum of rounds with a disclosed amount only
Named investors
2
Financing history
2 rounds
  1. May 29, 2025
    Form D equity offering · $125M (form d sold) · 15 investors
    Fact Form D · “Oric Pharmaceuticals, Inc. filed Form D: $125,000,000 sold of $125,000,000, Biotechnology”
  2. Jan 23, 2024
    Form D equity offering · $125M (form d sold) · 10 investors
    Fact Form D · “Oric Pharmaceuticals, Inc. filed Form D: $125,000,000 sold of $125,000,000, Biotechnology”
Investors on record
3 edges
Ownership and outcomes
2 on record, from the private equity graph and exit reports
  • Initial public offering · already an investor on record
    Apr 1, 20202 venture investors on record at exitFactcityhill.com
    “Oric Pharmaceuticals, Inc.: went public by IPO in 2020-04, per City Hill Ventures, LLC's portfolio page”
  • Listed in the portfolio of Viking Global Investors LP
    seen on or before Sep 15, 2026Private equity recordFactvikingglobal.com
    “portfolio card on https://vikingglobal.com/private-equity-portfolio/: ORIC Pharmaceuticals | Clinical-stage biopharmaceutical company developing therapies for treatment-resistant cancer | Investment s”
Credit relationships
none on record
No lender position matched to this company.
People
3 officers, 6 directors
Show all 6 officers and directors
Timeline
3 events
  1. Jun 6, 2025
    Oric Pharmaceuticals, Inc. filed Form D: $125,000,000 sold of $125,000,000, Biotechnology
    Form D filed Fact Form D
  2. Jan 30, 2024
    Oric Pharmaceuticals, Inc. filed Form D: $125,000,000 sold of $125,000,000, Biotechnology
    Form D filed Fact Form D
  3. Apr 1, 2020
    Oric Pharmaceuticals, Inc.: went public by IPO in 2020-04, per City Hill Ventures, LLC's portfolio page
    IPO Fact Firm website
Evidence
35 observations
Every observation on this company
  • Description: Sep 20, 2026 Fact no URL
  • Entity type: Corporation Jun 6, 2025 Fact Form D
  • Entity type: Corporation Jan 30, 2024 Fact Form D
  • Form D industry group: Biotechnology Jun 6, 2025 Fact Form D
  • Form D industry group: Biotechnology Jan 30, 2024 Fact Form D
  • Amendment: false Jun 6, 2025 Fact Form D
  • Amendment: false Jan 30, 2024 Fact Form D
  • Revenue range (Form D): Decline to Disclose Jun 6, 2025 Fact Form D
  • Revenue range (Form D): Decline to Disclose Jan 30, 2024 Fact Form D
  • Incorporated: overFiveYears Jun 6, 2025 Fact Form D
  • Incorporated: overFiveYears Jan 30, 2024 Fact Form D
  • Jurisdiction: Delaware Jun 6, 2025 Fact Form D
  • Jurisdiction: Delaware Jan 30, 2024 Fact Form D
  • Amount sold (Form D): $125M Jun 6, 2025 Fact Form D
  • Amount sold (Form D): $125M Jan 30, 2024 Fact Form D
  • Offering amount (Form D): $125M Jun 6, 2025 Fact Form D
  • Offering amount (Form D): $125M Jan 30, 2024 Fact Form D
  • Exemptions: 06b Jun 6, 2025 Fact Form D
  • Exemptions: 06b Jan 30, 2024 Fact Form D
  • First sale: 2025-05-29 Jun 6, 2025 Fact Form D
  • First sale: 2024-01-23 Jan 30, 2024 Fact Form D
  • Investors (Form D): 15 Jun 6, 2025 Fact Form D
  • Investors (Form D): 10 Jan 30, 2024 Fact Form D
  • Minimum investment (Form D): 0 Jun 6, 2025 Fact Form D
  • Minimum investment (Form D): 0 Jan 30, 2024 Fact Form D
  • Securities offered: Equity, option Jun 6, 2025 Fact Form D
  • Securities offered: equity Jan 30, 2024 Fact Form D
  • Office address: Jun 6, 2025 Fact Form D
  • Office address: Jan 30, 2024 Fact Form D
  • Listed on portfolio page: City Hill Ventures, LLC Sep 16, 2026 Fact Firm website
  • Listed on portfolio page: The Column Group Sep 16, 2026 Fact Firm website
  • Listed on portfolio page: City Hill Ventures, LLC Sep 14, 2026 Fact Firm website
  • Listed on portfolio page: The Column Group Sep 12, 2026 Fact Firm website
  • Website status: ok Sep 20, 2026 Fact no URL
  • Site title: Sep 20, 2026 Fact no URL

Relationships across DFX

on 1 other DFX graph
Across the graphs

Oric Pharmaceuticals, Inc. is the same institution as 1 record in Private Equity.

Private Equity1

The joined record opens with the product, beside every other relationship on this page.

Checking your plan…

Record history

1 identity change, 3 dated events on the change ledger, latest first
  • Merged in
    2026-09-13
  • Ipo
    2020-04-01source
  • Form D filed
    2024-01-30source

+1 more change on this record's ledger

Includes 3 days of DFX Intelligence. Then $199/month unless canceled.

The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.